Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data

Yu Yao, MD120 enrolled

Overview

This project intends to use multiple types of biological samples from glioma patients and mouse intracranial tumor models as research objects, and comprehensively apply a series of omics sequencing technologies and molecular biology technologies to jointly define the following research objectives :

1. Through high-throughput sequencing technologies such as， genome sequencing, transcriptome sequencing and single-cell sequencing, Proteomics，Metabonomics and Metagenomics， the similarities and differences of the glioma immune microenvironment within and between individuals were revealed from the multi-dimensional and big data level, and the immune molecular typing of glioma was established. 2. Establish and verify that the neoantigen polypeptides predicted by AI algorithm after analyzing multi-omics data (genome, transcriptome, etc.) have good killing effect on individual tumor cells. 3. To establish an intelligent evaluation model of glioma immunotyping by integrating imaging, pathology, high-throughput sequencing data and other omics information, and to provide a visual tool for monitoring changes in the intratumoral microenvironment of glioma patients, with the expectation of helping timely intervention of immunotherapy in patients with recurrence.

Study Type

OBSERVATIONAL

Enrollment

120

Conditions

Transcriptomics Radiomics Glioma

Interventions

surgeryPROCEDURE

surgery

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The patients with glioma in the Department of Neurosurgery of Huashan Hospital Affiliated to Fudan University who meet the following three conditions can be enrolled 1. They were 18-80 years old, male and female; 2. The pathological diagnosis was glioma; 3. On the basis of not affecting the clinical routine diagnosis, tissue (6 mm \* 6 mm) or paraffin section (5 pieces) can be used for research; 4. Sign informed consent or ethics committee approval Exclusion Criteria:

Locations (1)

Huashan hospital， Fudan University

Shanghai, China

RECRUITING

Outcomes

Primary Outcomes

Overall Survival（OS），month

Survival time from surgery to death in 120 patients with glioma.

Time frame: 24 month

Progress Free Survival （PFS），month

Survival time from surgery to first progression or death from any cause in patients with glioma.

Time frame: 24 month

Tumor Mutation Burden（TMB），mutations/mb, drived from Genomic sequencing

the level of gene mutation，including TERT、GMEM、IDH.etc.

Time frame: 24 month

Reads Per Kilobase Million（RPKM），KB^(-1), drived from Transcriptome sequencing

the expression level of RNA,including mRNA、 miRNA、circRNA.etc

Time frame: 24 month

expression level of protein , drived from Protein sequencing

the expression level of protein, post-translational modification and protein-protein interaction，including PD1、PDL1、CD4、CD8.etc.

Time frame: 24 month

expression level of low molecular weight protein，drived from Metabonomics

the expression level and interaction of different Metabolites，including D-2-Hydroxyglutarate. etc.

Time frame: 24 month

expression level of DNA，drived from Metagenomics

Differences about DNA expression of all microorganisms in the environment

Time frame: 24 month

frequency of TCR/BCR clone，drived from Immunomics

different expression level and interaction of Immune molecules，including TCR、BCR、antibody.etc.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.